These findings deepen the mechanistic understanding of ccRCC angiogenesis and underscore the ERβ/circAHNAK/FMR1/ADAM17 axis as a promising therapeutic target. This evidence concerns the gene ESR2 and nonpapillary renal cell carcinoma.